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Hunter syndrome (mucopolysaccharidosis type II [MPS II], OMIM309900) is a rare X-linked lysosomal storage disorder
caused by the deficiency of the enzyme iduronate-2-sulphatase, resulting in accumulation of glycosaminoglycans,
progressive multisystem organ failure, and early death. Enzyme replacement therapy (ERT) with weekly intravenous
infusions of idursulfase, a treatment for MPS II and commercially available since 2007, has been shown to improve
certain symptoms and signs of the disease. The efficacy and safety data of this enzyme preparation have been
widely reported and, after a change to the idursulfase Summary of Product Characteristics in March 2010, home ERT
by infusion is now an option for selected patients. Previously reported experiences of home therapy in MPS II have
shown increased treatment compliance and an improvement in quality of life for both patients and families. We
report the results of the home therapy experience of 3 paediatric patients with MPS II in southern Italy. This pilot
experience with home infusion is the first reported from Italy.
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(max 6)Introduction
Hunter syndrome or mucopolysaccharidosis type II (MPS
II) is an X-linked lysosomal storage disorder that is due to
a deficiency of iduronate-2-sulfatase, an enzyme essential
for the degradation and recycling of glycosaminoglycans
(GAGs). This enzyme deficiency results in a progressive
accumulation of GAGs in various tissues and organs.
Clinical manifestations include severe airway obstruction,
neurological decline, hepatosplenomegaly, skeletal defor-
mities, and cardiomyopathy. Death usually occurs in the
second decade of life [1].
Enzyme replacement therapy (ERT) for MPS II was
approved first in the US in 2006 [2]. Six years of experience
with this therapy has demonstrated the effectiveness of
ERT in slowing the accumulation of GAGs in various or-
gans such as the liver and spleen and in improving endur-
ance as measured by by the distance walked in 6 minutes.
However, no effects have been observed so far on the cen-
tral nervous system. The treatment is invasive and onerous,* Correspondence: dconcolino@unicz.it
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stated.involving weekly intravenous infusions over 4- to 5-hour
periods, which results in serious inconvenience for patients
and their families, who must spend a lot of time at the
treatment centre and consequently face disruption to their
normal life. In addition, in southern Italy the treatment
centres where the therapy is administered are often far
from where the patients live and therefore difficult or time
consuming to reach. This has a negative impact on the
family budget (travel expenses, workdays missed), on com-
pliance with therapy, and on quality of life [3].
Given the positive reports of home therapy in patients
with MPS II from other European and worldwide cen-
tres [4-7] and the ongoing successful experiences of
home treatment in patients with Fabry disease in Italy,
we expanded this care model to patients suffering from
MPS II and followed them at our Hospital Unit. Here
we report the results of our experience in southern Italy
with 3 patients with Hunter syndrome who have been
undergoing home treatment for 73 to 87 weeks.Patients and methods
Three patients affected with MPS II, aged between 6 and
14 years and treated in our centre with ERT, startedal Ltd. This is an Open Access article distributed under the terms of the Creative
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type of the patients was classified according to cognitive
impairment. All patients showed stable disease, had
experienced at least 12 months of previous ERT in
hospital, and had not reported adverse drug reactions
during the last 3 months of therapy. No patients needed
pre-medication during home therapy. No patients had
surgical support placement or severe respiratory failure
(FEV <40%). Nursing staff were selected according to
their technical skills and their competence in paediatric
basic life support (PBLS) and treatment of adverse drug
reactions. All nurses involved in the project received
dedicated training in lysosomal storage disorders with a
focus on MPS II. They were also trained in medication
handling, storage, reconstitution, and administration,
as well as in potential adverse event recognition and
management. Each patient was assigned to a specific
nurse who had experience with enzyme infusion treat-
ment under physician supervision. Nurses met with
the patients’ families and agreed on the date and time
of the first home infusion. All nurses were equipped
with a pump and infusion kits, monitors for assess-
ment of vital signs, oxygen, and first aid drugs for
adverse events.
In order to manage any home treatment–related com-
plications that might arise, a “security care network” was
set up for patients. The main components of this net-
work were the reference centre, nurses, patients’ fam-
ilies, family doctors, and the patients’ local hospitals.
The reference centre (University Pediatrics Department.
Rare and Metabolic Diseases Unit. Magna Graecia Univer-
sity – Catanzaro) acted as coordinator and approver. The
start date for infusions was decided on the basis of clinical
data as reported by the nurse. Each patient’s family doctor
was alerted in case of illness or when the nurses or the ref-
erence centre believed it to be appropriate. The local hos-
pital was ready to intervene in case of severe drug adverse
reactions. The reference centre received a clinical report
each month from the nurses in order to follow the clinical
evolution of the patients’ disease.Table 1 Infusion therapy in patients with MPS II
Patient 1 Patient 2 Patient 3
Age at diagnosis 4 y 9 mo 1 y 8 mo 7 y 8 mo
Phenotype severe severe mild
Age at start of ERT 4 y 11 mo 2 y 5 mo 11 y 3 mo
ERT at hospital (number of infusions) 69 157 128
ADRs at hospital 0 2 1
Age at start of ERT at home 6 y 4 mo 6 y 2 mo 16 y 2 mo
ERT at home (number of infusions) 87 73 74
ADRs at home 0 0 0
ADR adverse drug reaction, ERT enzyme replacement therapy.Compliance was the main parameter affecting effect-
iveness which was evaluated for home therapy. The fre-
quency of infusions missed during home treatment was
compared with the frequency of missed infusions
observed for hospital treatment. Safety parameters were
also recorded. These included number and type of
adverse reactions, and number of missed infusions
reported to the home health-care team. Parents were
asked to complete a quality-of-life form using a validated
questionnaire (EQ-5D) at the start of the treatment and
after 1, 3, and 6 months. EQ-5D is a standardized instru-
ment used as a measure of health outcomes [8,9].
The financial impact of home treatment was also
examined, particularly with regard to associated travel
costs and reductions in income due to missed workdays.
The project was approved by the ethics committee of
the Ospedale Civile Pugliese Ciaccio.
Results
After appropriate counselling concerning the potential
risks and benefits, provided by the reference centre, the
parents of all 3 patients agreed to home infusion.
Table 1 shows patient profiles and the number of infu-
sions administered at home and at the hospital. During
the first year of home treatment, more infusions were
administered at home than had been administered at the
specialised centre in the year previous to starting home
treatment. Patients 1, 2, and 3 received 52, 52, and 51
infusions at home, respectively, compared with 49, 48,
and 49 infusions at the hospital the year before. Also,
the number of missed infusions was higher when the
patients went for hospital treatment (3, 4, and 3 infusions
were missed by patients 1, 2, and 3, respectively). This
compares with only 1 missed infusion (due to temporary
sickness in patient 3) when on home treatment. Reasons
for missed infusions at the hospital included illness of
patients or caregivers, and transportation problems.
The EQ-5D proxy scores of the patients’ parents
increased when the patient was on home treatment,
indicating an important improvement in quality of
life. For families 1, 2, and 3 the baseline EQ-5D scores
were −0.352, +0.011, and −0.181, respectively. After
1 month the scores were +0.137, +0.516, and +0.110, and
at 6 months they were +0.367, +0.746, and +0.746 for
families 1, 2, and 3, respectively.
Cost analysis revealed that home treatment resulted in
an average savings of 11,000 euros per family during the
study (range: 9,048–12,324 euros). Of this amount, 41%
(range 28%–47%) was attributable to the costs of weekly
travel from home to the hospital, and the remaining 59%
(range 54%-72%) to family members not missing
workdays.
No adverse reactions were reported during 234 home
infusions.
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Our experience demonstrates that home treatment with
Elaprase is feasible and safe for selected patients with
MPS II, as has been reported in other European and
worldwide centres [4,6]. A significant benefit of this
reported home therapy is that patients showed an almost
perfect compliance with the treatment schedule. Home
therapy is effective in helping to avoid missed infusions
due to non-clinical reasons and helps to guarantee an
adequate infusion schedule since it increases scheduling
flexibility. Home therapy also helps to alleviate the
burden of lifelong therapy in these patients and their
families, as demonstrated by the improved quality of life
shown by the increased EQ-5D proxy questionnaire
scores. This occurred mainly in the areas of "usual acti-
vity" and "anxiety/depression" demonstrating that home
care was perceived as less invasive and more compatible
with the daily activities. According to this data, home
treatment, appears to give families and patients a better
perception of the disease. Obviously, given the functional
and cognitive limitations of patients with Hunter disease
it was unlikely to expect further improvements in the
areas of "self care", "mobility" and "pain/discomfort".
Cost analysis shows that home therapy also lowers the
impact of ERT on the family budget.
In conclusion, on the basis of our experience, home
therapy should be a clear and logical choice for the man-
agement of selected MPS II patients, including those with-
out severe chronic obstructive airway disease (FEV < 40%)
who have been treated with ERT for at least 6 months at
the hospital and have been without adverse drug reactions
for the last 3 months.
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